Multiple Sclerosis, Relapsing-Remitting Clinical Trial
Official title:
Investigation of the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Individuals Diagnosed With Relapsing-Remitting Multiple Sclerosis
NCT number | NCT06129019 |
Other study ID # | 22/11 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | December 1, 2023 |
Est. completion date | June 1, 2024 |
During Reiki application, individuals may report feeling a slight warm sensation under and near the therapist's hand. The only rule in Reiki practice is that the individual must give permission to the practitioner to facilitate the flow of energy. The person receiving Reiki during the application does not have to believe in Reiki. Because Reiki is universal life energy and is available to everyone. Reiki is generally safe and no serious side effects have been reported. Reiki practice in the last 10 years; It is increasing among physicians, nurses and other healthcare professionals. This study was planned to investigate the effect of reiki application on depression, anxiety and physical activity in individuals diagnosed with Relapsing-Remitting Multiple Sclerosis. Geri bildirim gönder Yan paneller
Status | Recruiting |
Enrollment | 60 |
Est. completion date | June 1, 2024 |
Est. primary completion date | March 20, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Being over 18 years of age - Having the ability to use technological devices - Not using Reiki and similar integrative treatment methods - No verbal communication disability (hearing and speaking) - Not having a diagnosed psychiatric disorder - Patients who have been receiving Relapsing-Remitting MS treatment for more than three months Exclusion Criteria: - Patients using any complementary alternative treatment methods - Patients who cannot communicate by phone to participate in remote reiki application - Patients with autoimmune diseases other than multiple sclerosis - Patients with communication disabilities - Patients with another known neurological system disease (dementia, Alzheimer's, etc.). |
Country | Name | City | State |
---|---|---|---|
Turkey | Firat University | Elazig |
Lead Sponsor | Collaborator |
---|---|
Ataturk University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Beck Depression Scale | The scale was administered to investigate each participant's feelings and attitudes regarding the general depressive state. Each patient was asked to read several groups of statements and then mark the one statement in each group that best described how he or she felt "during the past week." BDI, which evaluates four statements describing increasing intensities of depressive symptoms between 0 and 3 points, includes 21 items. Depressive symptoms were classified as follows: minimal-to-moderate depressive symptoms (range 14 to 19), moderate-to-severe depressive symptoms (range 20 to 29), severe depressive symptoms (range 30 to 63). | 4 week | |
Primary | Beck Anxiety Scale | BAI is a self-rating scale developed by Beck et al. (1988) and used to determine the frequency of anxiety symptoms experienced by individuals. It is a Likert-type scale consisting of 21 items and scored between 0-3. Its validity and reliability in Turkey were determined by Ulusoy et al. | 4 week | |
Primary | International Physical Activity Survey | There are some scales that can be used in primary care to evaluate physical mobility. One of these is the "International Physical Activity Questionnaire", which was developed by the International Consensus Group consisting of researchers from various countries with the support of the World Health Organization and the Center for Disease Control, to be used to measure physical activity and inactivity in 1997 and 1998; (IPAQ)" is a standard tool. Reliability and/or validity studies were conducted in 14 centers from 12 countries in 2000 for at least two of the four long (IPAQ-long) and four short (IPAQ-SF) forms of the IPAQ. This scale was adapted into Turkish as long form (UF) and short form (SF) under the name "International Physical Activity Questionnaire (UFAA)" and its validity and reliability study was conducted by Saglam et al. in 2010 | 4 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02861014 -
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
|
Phase 3 | |
Terminated |
NCT01435993 -
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
|
Phase 1 | |
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02410200 -
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
|
Phase 2 | |
Completed |
NCT03975413 -
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
|
||
Completed |
NCT05080270 -
Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis
|
Early Phase 1 | |
Completed |
NCT01116427 -
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01108887 -
An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmartâ„¢.
|
N/A | |
Completed |
NCT01141751 -
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
|
N/A | |
Completed |
NCT00097331 -
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01909492 -
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
|
||
Completed |
NCT04121221 -
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
|
Phase 3 | |
Withdrawn |
NCT04880577 -
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT05290688 -
Cellular microRNA Signatures in Multiple Sclerosis
|
N/A | |
Completed |
NCT04528121 -
Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT04002934 -
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT05019248 -
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
|
||
Completed |
NCT04580381 -
Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
|
||
Completed |
NCT00071838 -
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 2 |